Ikena Oncology, Inc. (IKNA): Price and Financial Metrics
IKNA Price/Volume Stats
| Current price | $1.30 | 52-week high | $1.94 |
| Prev. close | $1.34 | 52-week low | $0.97 |
| Day low | $1.30 | Volume | 30,100 |
| Day high | $1.35 | Avg. volume | 116,608 |
| 50-day MA | $1.18 | Dividend yield | N/A |
| 200-day MA | $1.50 | Market Cap | 62.74M |
IKNA Stock Price Chart Interactive Chart >
Ikena Oncology, Inc. (IKNA) Company Bio
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
IKNA Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IKNA Price Returns
| 1-mo | 19.27% |
| 3-mo | -9.72% |
| 6-mo | -22.62% |
| 1-year | -26.14% |
| 3-year | -69.34% |
| 5-year | N/A |
| YTD | -20.73% |
| 2024 | -16.75% |
| 2023 | -25.94% |
| 2022 | -78.79% |
| 2021 | N/A |
| 2020 | N/A |